Treatment of non-Hodgkin's lymphomas in elderly patients

Clinical Lymphoma

Volumn 5, Issue 1, 2004, Pages 37-44

  Bordonaro, Roberto ^a   Fratino, Lucia ^b   Serraino, Diego ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Chemotherapy; Prognostic factors; Quality of life; Toxicity

Indexed keywords

ALPHA INTERFERON A; AMIFOSTINE; ANTHRACYCLINE; BLEOMYCIN; CD11B ANTIGEN; CD16 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GRANULOCYTE COLONY STIMULATING FACTOR; LACTATE DEHYDROGENASE; METHOTREXATE; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TENIPOSIDE; VINCRISTINE;

AGED; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKOPENIA; LITERATURE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4344619957     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2004.n.008     Document Type: Review

References (58)

1. Devesa SS, Silverman DT, Young JL Jr, et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987; 79:701-770.
2. Barnes N, Cartwright RA, O'Brien C, et al. Rising incidence of lymphoid malignancies-true or false? Br J Cancer 1986; 53:393-398.
3. Peters FP, Lalisang RI, Fickers MM, et al. Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 2001; 80:155-159.
4. Cancer Statistics Review 1975-2000. SEER database from the National Cancer Institute.
5. Goss PE. Non-Hodgkin's lymphomas in elderly patients. Leuk Lymphoma 1993; 10:147-156.
6. Neilly IJ, Ogston M, Bennett B, et al. High grade non-Hodgkins lymphoma in the elderly - 12-year experience in the Grampian Region of Scotland. Hematol Oncol 1995; 13:99-106.
7. Dumontet C, Mounier N, Munck JN, et al. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Br J Haematol 2002; 118:210-217.
8. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001; 2:47-56.
9. Hancock BW, Aitken M, Radstone C, et al. Why don't cancer patients get entered into clinical trials? Experience of the Sheffield Lymphoma Group's collaboration in British National Lymphoma Investigation studies. Br Med J 1997; 314:36-37.
10. Culliton BJ. Easier access to clinical trials. Nat Med 1997; 4:369.
11. Bordonaro R, Serraino D, Ritossa D, et al. Costi del trattamento di pazienti anziani (pa) affetti da linfoma: Confronto tra terapie standard e protocolli di studio, Tumori in eta Geriatrica; December 3-5, 1997; Rome, Italy.
12. Serraino D, Zagonel V, Bordonaro R, et al. Why are patients with malignant lymphomas excluded from clinical trials? The experience of an oncology institute in Italy. Eur J Cancer 1998; 34:427-428.
13. Chen CI, Skingley P, Meyer RM. A comparison of elderly patients with aggressive histology lymphoma who were entered or not entered on to a randomized phase II trial. Leuk Lymphoma 2000; 38:327-334.
14. d'Amore F, Brincker H, Christensen BE, et al. Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol 1992; 3:379-386.
15. Bordonaro R, Ricotta R, Restuccia N, et al. Outcome in aggressive non-Hodgkin's lymphomas in the elderly: A restrospective analysis in patients treated with anthracycline-based regimens. Blood 2002; 100(suppl):293b (Abstract #4708).
16. Bordonaro R, Ricotta R, Restuccia N, et al. Anthracycline-based regimens may induce high response rate and impressive 2-year survival in patients older than 60 years affected by B-line, diffuse large-cell lymphomas. A retrospective analysis of an Italian community hospital. Proc Am Assoc Cancer Res 2003; 44:341 (Abstract #1510).
17. Carbone A, Volpe R, Gloghini A, et al. Non-Hodgkin's lymphoma in the elderly. I. Pathologic features at presentation. Cancer 1990; 66:1991-1994.
18. Dumontet C, Anderson JR, Sebban C, et al. Elderly non-Hodgkin's lymphoma patients have comparable prognostic factors but a poorer outcome than younger patients. Proc Am Soc Clin Oncol 1992; 11 (Abstract #1118).
19. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-994.
20. Lopez-Guillermo A, Montserrat E, Bosch F, et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12:1343-1348.
21. Decaudin D, Lepage E, Brousse N, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients - a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999; 17:2499-2505.
22. Fried LP, Bandeen-Roche K, Kasper JD, et al. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol 1999; 52:27-37.
23. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36:453-471.
24. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006.
25. Shipp MA, Yeap BY, Harrington DP, et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol 1990; 8:84-93.
26. Dana BW, Dahlberg S, Miller TP, et al. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. J Clin Oncol 1990; 8:1155-1162.
27. Connors JM, Klimo P. MACOP-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations. Semin Hematol 1988; 25:41-46.
28. Miller TP, Dahlberg S, Cassady JR, et al. Three cycles of CHOP plus radiotherapy is superior to eight cycles of CHOP alone for localized intermediate and high grade non-Hodgkin's lymphoma (NHL): A Southwest oncology group study. Proc Am Soc Clin Oncol 1996; 15 (Abstract #1257).
29. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984; 32:269-273.
30. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4:295-305,
31. O'Connell MJ, Earle JD, Harrington DP, et al. Initial chemotherapy doses for elderly patients with malignant lymphoma. J Clin Oncol 1986; 4:1418.
32. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6:1838-1844.
33. Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327:1342-1349.
34. Cooper IA, Wolf MM, Robertson TI, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol 1994; 12:769-778.
35. Montserrat E, Garcia-Conde J, Vinolas N, et al. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology. Eur J Haematol 1996; 57:377-383.
36. Wolf M, Matthews JP, Stone J, et al. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. Ann Oncol 1997; 8(suppl 1):71-75.
37. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16:27-34.
38. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
39. Pfeundschuh M, Trumper L, Kloess M, et al. 2-weekly CHOP (CHOP-14): The new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) > 60 years of age. Ann Oncol 2002; 13(suppl 2):27 (Abstract #081).
40. Bessell EM, Burton A, Haynes AP, et al. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14:258-267.
41. Tirelli U, Zagonel V, Serraino D, et al. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study. J Clin Oncol 1988; 6:1708-1713.
42. Tirelli U, Zagonel V, Sorio R, et al. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavourable non-Hodgkin's lymphoma: A prospective study in 52 patients. Semin Hematol 1994; 31(2 suppl 3):13-22.
43. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13:2530-2539.
44. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003; 101:3840-3848.
45. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94:33-38.
46. Zinzani PL, Gherlinzoni F, Storti S, et al. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 2002; 13:1364-1369.
47. Sacco C, Zagonel V, Merola MC, et al. Chemioterapia di combinazione associata a G-CSF a cicli alterni, in pazienti anziani affetti da linfoma non-Hodgkin. Tumori 1994; 80:85 (Abstract #194).
48. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89:3974-3979.
49. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 21:3041-3050.
50. Osby E, Bjorkholm M, Lundahl J, et al. Granulocyte function in elderly patients receiving chemotherapy for aggressive non-Hodgkin's lymphoma. Effect of granulocyte colony-stimulating factor. Eur J Intern Med 2002; 13:448.
51. Spath-Schwalbe E, Lange C, Genvresse I, et al. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma - a phase II study. Anticancer Drugs 2002; 13:395-403.
52. Khouri I, Romaguera J, Kantarjian H, et al. HyperCVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: An active regimen for agressive mantle cell lymphoma. J Clin Oncol 1998; 16:3803-3809.
53. Romaguera J, Cabanillas F, Dang N, et al. Mantle cell lymphoma - high rates of complete remission and prolonged failure free survival with Rituxan-HyperCVAD without stem cell transplantation. Blood 2001; 98(suppl):631a (Abstract #2804).
54. Coiffier B, Neidhardt-Berard EM, Tilly H, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 1999; 10:1191-1197.
55. Bordonaro R, Petralia G, Restuccia N, et al. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study. Leuk Lymphoma 2004; 45:93-100.
56. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14:1262-1268.
57. Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol 2000; 11:363-365.
58. Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 2002; 20:4261-4267.